Effective use of the upper limb can impact on educational outcomes, participation in
activities of daily living and vocational options for many children with cerebral palsy (CP) …

Botulinum neurotoxin type‐A (BoNT‐A) has been used in association with other
interventions in the management of spasticity in children with cerebral palsy (CP) for almost …

Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. - Abstract -
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …

Management of children with cerebral palsy (CP) is the focus of considerable resources in
many countries, so that evaluation of the efficacy for new and established treatments is …

Abstract Background Use of Botulinum toxin-A (BoNT-A) for treatment of upper limb
spasticity in children with cerebral palsy has become routine clinical practice in many …

Botulinum toxin type A (BoNT-A) therapy has gained wide acceptance in the management of
spasticity in cerebral palsy (CP). Clinical experience from numerous case reports and series …

Objective: This systematic review provides an overview of the effectiveness of conceptual
approaches and additional therapies used in lower limb physical therapy of children with …

Background Cerebral palsy (CP) is a central nervous system deficit resulting from a non‐
progressive lesion in the developing brain. Although the brain lesions are static, the …

Currently there is no specific treatment for the brain insults leading to motor dysfunction in
cerebral palsy. The available symptomatic therapeutic options place cerebral palsy among …

The aim of this article is to describe our clinical experience in treating muscle imbalance in
49 children with spastic upper extremity involvement. We discuss four cohorts of children …